FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2320131143> ?p ?o ?g. }

• W2320131143 endingPage "8167" @default.
• W2320131143 startingPage "8158" @default.
• W2320131143 abstract "The organotin(IV) compounds [Me(2)Sn(L)(2)] (1), [Et(2)Sn(L)(2)] (2), [(n)Bu(2)Sn(L)(2)] (3), [(n)Oct(2)Sn(L)(2)] (4), [Ph(2)Sn(L)(2)] (5), and [PhOSnL](6) (6) have been synthesized from the reactions of 1-(4-chlorophenyl)-1-cyclopentanecarboxylic acid (HL) with the corresponding diorganotin(IV) oxide or dichloride. They were characterized by IR and multinuclear NMR spectroscopies, elemental analysis, cyclic voltammetry, and, for 2, 3, 4 and 6, single crystal X-ray diffraction analysis. While 1-5 are mononuclear diorganotin(IV) compounds, the X-ray diffraction of 6 discloses a hexameric drumlike structure with a prismatic Sn(6)O(6) core. All these complexes undergo irreversible reductions and were screened for their in vitro antitumor activities toward HL-60, BGC-823, Bel-7402, and KB human cancer cell lines. Within the mononuclear compounds, the most active ones (3, 5) are easiest to reduce (least cathodic reduction potentials), while the least active ones (1, 4) are the most difficult to reduce. Structural rearrangements (i.e., Sn-O bond cleavages and trans-to-cis isomerization) induced by reduction, which eventually can favor the bioactivity, are disclosed by theoretical/electrochemical studies." @default.
• W2320131143 created "2016-06-24" @default.
• W2320131143 creator A5026175853 @default.
• W2320131143 creator A5045499776 @default.
• W2320131143 creator A5054433231 @default.
• W2320131143 creator A5059561651 @default.
• W2320131143 creator A5061527997 @default.
• W2320131143 creator A5081080106 @default.
• W2320131143 creator A5081571915 @default.
• W2320131143 date "2011-07-27" @default.
• W2320131143 modified "2023-09-25" @default.
• W2320131143 title "Syntheses, Molecular Structures, Electrochemical Behavior, Theoretical Study, and Antitumor Activities of Organotin(IV) Complexes Containing 1-(4-Chlorophenyl)-1-cyclopentanecarboxylato Ligands" @default.
• W2320131143 cites W1498394482 @default.
• W2320131143 cites W1606806395 @default.
• W2320131143 cites W1629179716 @default.
• W2320131143 cites W1964759669 @default.
• W2320131143 cites W1969345055 @default.
• W2320131143 cites W1971152615 @default.
• W2320131143 cites W1973184519 @default.
• W2320131143 cites W1985000946 @default.
• W2320131143 cites W1994838738 @default.
• W2320131143 cites W1995698404 @default.
• W2320131143 cites W1997476747 @default.
• W2320131143 cites W1997657471 @default.
• W2320131143 cites W2002635047 @default.
• W2320131143 cites W2010581663 @default.
• W2320131143 cites W2014455084 @default.
• W2320131143 cites W2015949376 @default.
• W2320131143 cites W2017356685 @default.
• W2320131143 cites W2019061601 @default.
• W2320131143 cites W2019215249 @default.
• W2320131143 cites W2021017189 @default.
• W2320131143 cites W2021367505 @default.
• W2320131143 cites W2023271753 @default.
• W2320131143 cites W2027846033 @default.
• W2320131143 cites W2028463461 @default.
• W2320131143 cites W2028599275 @default.
• W2320131143 cites W2030864703 @default.
• W2320131143 cites W2032055912 @default.
• W2320131143 cites W2033494335 @default.
• W2320131143 cites W2033862487 @default.
• W2320131143 cites W2034117095 @default.
• W2320131143 cites W2037270587 @default.
• W2320131143 cites W2038767330 @default.
• W2320131143 cites W2039901816 @default.
• W2320131143 cites W2041869855 @default.
• W2320131143 cites W2042080227 @default.
• W2320131143 cites W2043327592 @default.
• W2320131143 cites W2053194923 @default.
• W2320131143 cites W2053382382 @default.
• W2320131143 cites W2054561189 @default.
• W2320131143 cites W2057161941 @default.
• W2320131143 cites W2060170206 @default.
• W2320131143 cites W2063074480 @default.
• W2320131143 cites W2064380750 @default.
• W2320131143 cites W2064398928 @default.
• W2320131143 cites W2064586647 @default.
• W2320131143 cites W2065593325 @default.
• W2320131143 cites W2069250627 @default.
• W2320131143 cites W2070711340 @default.
• W2320131143 cites W2072081100 @default.
• W2320131143 cites W2072902454 @default.
• W2320131143 cites W2073630192 @default.
• W2320131143 cites W2076311455 @default.
• W2320131143 cites W2077144818 @default.
• W2320131143 cites W2077716969 @default.
• W2320131143 cites W2079885754 @default.
• W2320131143 cites W2081334723 @default.
• W2320131143 cites W2084853179 @default.
• W2320131143 cites W2088232562 @default.
• W2320131143 cites W2091753792 @default.
• W2320131143 cites W2093243373 @default.
• W2320131143 cites W2100402476 @default.
• W2320131143 cites W2109689528 @default.
• W2320131143 cites W2123382183 @default.
• W2320131143 cites W2131350133 @default.
• W2320131143 cites W2131547351 @default.
• W2320131143 cites W2132994053 @default.
• W2320131143 cites W2143981217 @default.
• W2320131143 cites W2146005920 @default.
• W2320131143 cites W2147288727 @default.
• W2320131143 cites W2148066840 @default.
• W2320131143 cites W2151473259 @default.
• W2320131143 cites W2154228453 @default.
• W2320131143 cites W2154339570 @default.
• W2320131143 cites W2155688568 @default.
• W2320131143 cites W2487770617 @default.
• W2320131143 cites W3139161328 @default.
• W2320131143 cites W4211014085 @default.
• W2320131143 cites W4231374710 @default.
• W2320131143 cites W4292428312 @default.
• W2320131143 cites W4375905875 @default.
• W2320131143 doi "https://doi.org/10.1021/ic200635g" @default.
• W2320131143 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21793560" @default.
• W2320131143 hasPublicationYear "2011" @default.
• W2320131143 type Work @default.
• W2320131143 sameAs 2320131143 @default.
• W2320131143 citedByCount "81" @default.

• next